media – Page 30 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Additional clinical trial data for pediatric patients is needed. Tian Tan Biologics has withdrawn its application for the market release of a hemophilia treatment drug.

More than 10 months after its submission, Tian Tan Biologics (SH600161, stock price 17.61 yuan, market capitalization 34.822 billion yuan) withdrew its application for listing of a hemophilia drug that cost 266 million yuan to develop. On the evening of November 19th, this leading domestic blood product company released a statement, stating that its subordinate enterprise, Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Rongsheng), withdrew the drug registration application for “Recombinant Human Coagulation Factor VIIa for Injection”. The reason was that according to the review opinions of the CDE (National Medical Products Administration Drug Evaluation Center), supplementary information was required. It became the first domestically produced recombinant human coagulation factor VIIa biological product to be approved for market launch in China. However, from the indication perspective, Anqixin’s application scope is much smaller than Nuoqi. The products under Tian Tan Biotechnology are more similar to Nokir. On December ...
- Source: drugdu
- 98
- November 27, 2025
CSPC Pharmaceutical Group Limited ‘s clinical trial for the recombinant fully human anti-ACTRIIA/IIB monoclonal antibody has been approved

Beijing Business News (Reporter Wang Yinhao, Song Yuying) – On November 26th, Shigao Group announced that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug (JMT206) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The announcement shows that this product can specifically bind to both activin receptor type IIA and type IIB simultaneously, blocking the binding of activin A, myostatin, and growth differentiation factor 11 to activin receptor type II, thereby inhibiting the activation of downstream signaling pathways, reducing muscle loss, and promoting the maintenance and growth of skeletal muscles, achieving the effect of muscle gain and fat loss. At the same time, this product can also assist GLP-1 receptor agonists in achieving higher-quality weight loss efficacy. The approved clinical indication for this approval is weight management for obese or overweight individuals with at least one weight-related comorbidity. https://finance.eastmoney.com/a/202511263575661579.html
- Source: drugdu
- 98
- November 27, 2025
Seven Essential Steps for Successfully Bringing Pharmaceutical Products to the Global Market

In the process of bringing pharmaceutical products into global markets, every step from R&D to launch, from compliance to marketing, is full of challenges. Traditional approaches often rely on single channels or offline networks. However, against the backdrop of accelerating digitalization and cross-border trade, leveraging a professional platform to operate in a systematic way has become increasingly indispensable. Based on practical experience from the Drugdu.com platform, this article systematically summarizes the seven key steps that must be done well for product launch, for reference by pharmaceutical manufacturers, exporters and service providers. I. Conduct in-depth market research The launch of any pharmaceutical or medical device product should be grounded in solid market insights, including: Competitive landscape analysis: Study competitors’ pricing structures, sales channels and distribution models to support clear product positioning. Customer needs identification: Not only patients, but also medical institutions, purchasing bodies and agents. Through interviews, surveys and industry data, identify unmet ...
- Source: drugdu
- 192
- November 27, 2025
CDMEE Chengdu

Organiser：Sichuan Provincial Hospital Association, Sichuan Medical Device Industry Association, Sichuan Rehabilitation Medicine Association Time： March 17 – 19, 2026 Address：No. 198, Shijicheng Road, Chengdu, Sichuan Province Exhibition hall：Chengdu Century City New International Convention & Exhibition Center Product range: Medical Equipment Exhibition Area: Imaging equipment, in vitro diagnostic reagents and instruments, disinfection and infection control series, medical electronic equipment, medical vehicles, operating room and emergency equipment, medical consumables and surgical consumables, medical maintenance parts and consumables, etc. Medical Laboratory Exhibition Area: Medical analysis systems, gene and life science instruments, laboratory case equipment and consumables, clinical laboratory equipment and consumables, blood collection management systems and blood transfusion supplies, blood and cell analysis systems, clinical laboratory equipment parts and maintenance consumables, etc. Rehabilitation and Well-being Exhibition Area: Sensory integration training equipment, disability aids and supplies, rehabilitation and physiotherapy equipment, sensory interaction equipment, assistive devices, etc.; sensory integration training equipment, disability equipment and supplies, ...
- Source: drugdu
- 122
- November 27, 2025
Gan & Lee Pharmaceuticals’ innovative drug licensing lands in the Latin American market, marking the start of its commercialization strategy in the region

On November 25th, Gan & Lee Pharmaceuticals…(603087) announced that it has entered into an exclusive licensing and commercialization agreement with Productos Científicos SA de CV (hereinafter referred to as PC), a well-known pharmaceutical company in Latin America, authorizing PC to develop and commercialize Bovangravitide (GZR18), a bi-weekly formulation of glucagon-like peptide-1 receptor agonist (GLP-1RA), independently developed by Gan & Lee Pharmaceuticals, in Latin America (including key countries such as Mexico and Brazil). This collaboration marks the first time that Gan & Lee Pharmaceuticals has achieved independent innovation in drug development.This international expansion has also opened up a new commercialization strategy for Gan & Lee’s innovative drugs in Latin America. The Latin American GLP-1 market has huge potential and bi-weekly formulations have significant advantages. This collaboration combines Gan & Lee Pharmaceuticals ‘ innovative R&D capabilities with the partner’s local strengths to jointly explore a rapidly growing market. Public data shows that ...
- Source: drugdu
- 211
- November 26, 2025
Fosun Pharma and Ruizhi Pharma Reach Strategic Cooperation

On November 25th, Fosun Pharma and Ruizhi Pharma…A strategic cooperation framework agreement signing ceremony was held in Shanghai. Li Xiang, Senior Vice President and CEO of the Global R&D Center of Fosun Pharma , stated that in the future, leveraging the full-chain R&D service capabilities of Ruizhi Pharma , Fosun Pharma is expected to further improve the efficiency and quality of its drug development across various drug types, accelerate the transformation of innovative achievements, and consolidate its competitive advantage in the field of innovative medicine. At the same time, the cooperation between the two parties sets a benchmark for the industry with a “technology-driven innovation platform + service platform” model, which will help promote the efficient integration of upstream and downstream resources in the industry chain, contribute to improving the overall level of new drug development in China, and bring more high-quality treatment options to more patients. https://finance.eastmoney.com/a/202511253574517765.html
- Source: drugdu
- 107
- November 26, 2025
Aurisco’s wholly-owned subsidiary received the marketing authorization for its Estradiol Tablets

November 25 – Aurisco (605116) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging. The dosage form is tablets, with specifications as follows: each Estradiol Tablet contains 2mg of estradiol, and each Estradiol and Dydrogesterone Tablet contains 2mg of estradiol and 10mg of dydrogesterone. As of October 31, 2025, the cumulative R&D investment in this drug project by the company amounted to approximately RMB 12.64 million. This product is a dydrogesterone compound preparation originally developed by Abbott. It is used to treat perimenopausal syndrome caused by natural or surgical menopause. In 2015, the Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging, applied for by Abbott as an imported drug, was approved for marketing in China under the brand name “Femoston®”. Data from ...
- Source: drugdu
- 105
- November 26, 2025
Hengrui Pharma’s Ruikang Trastuzumab for Injection Wins Clinical Trial Approval

Beijing Business Today, Nov. 25 – Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for Ruikang Trastuzumab for Injection, approving the monotherapy clinical trial in patients with HER2-amplified solid tumors. According to the announcement, Ruikang Trastuzumab for Injection binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosomes, the toxin is released through protease cleavage, inducing cell cycle arrest and triggering tumor cell apoptosis. The released toxin exhibits high membrane permeability, enabling a bystander killing effect that further enhances anti-tumor efficacy. Ruikang Trastuzumab for Injection was approved for marketing in China in May 2025, indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one line of systemic ...
- Source: drugdu
- 99
- November 26, 2025
AI-driven drug development partnership reaches $3 billion

Merck recently announced a strategic collaboration agreement with Valo Health, potentially worth up to $3 billion, aimed at accelerating the development of innovative treatments for Parkinson’s disease using artificial intelligence (AI) and machine learning technologies. Under the terms of the agreement, Merck will make an undisclosed upfront payment to Valo Health and commit to additional payments totaling up to $3 billion upon achieving specific R&D, regulatory approvals, and commercialization milestones. The collaboration also includes R&D funding and tiered royalties on future product sales. The division of labor between the two parties is clear: Valo Health will utilize its self-developed Opal computing platform to be responsible for the early identification of drug targets and the design and optimization of candidate molecules; Merck will be responsible for subsequent clinical development, registration and application, and global commercialization. This collaborative model of “AI biotechnology company + traditional pharmaceutical company” is becoming the mainstream in ...
- Source: drugdu
- 202
- November 26, 2025
Honz Pharmaceutical Co., Ltd. has received the approval notice for the clinical trial of the cough-relieving orange-red granules drug

Beijing Business News (Reporter Ding Ning) – On the evening of November 25th, Honz Pharmaceutical Co., Ltd. (300086) issued a statement, announcing that recently, the company’s “Cough Suppressant Juhong Granules” has obtained the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The announcement shows that Cough Suppressant Juhong Granules is a product that the company has already produced and is currently on sale. It was originally a national second-level protected traditional Chinese medicine variety (with a protection period until September 13, 2016), and its current indications are “clearing the lungs, suppressing cough, and resolving phlegm. It is used for cough with excessive phlegm, chest fullness, shortness of breath, dry throat and itchy throat caused by phlegm heat blocking the lungs.” Based on the latest clinical research and expert consensus, the company submitted a clinical trial application to add a new indication of “acute exacerbation of chronic ...
- Source: drugdu
- 90
- November 26, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.